A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

NCT01392573 · Completed

Last updated 2026-05-28

This trial compares two diabetes treatments—insulin degludec/liraglutide and insulin degludec alone—in adults with type 2 diabetes to see how they affect blood sugar control.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 413 people

Who can join Ages 18+ · all sexes

Timeline Started 2011-11 · est. completion 2012-10

Where 86 sites · Bulgaria, Denmark, Hungary, India, Slovenia, Switzerland, United States

What this study is testing ClinicalTrials.gov NCT01392573 ↗

Description as written by the study sponsor.

This trial is conducted in Asia, Europe and the United States of America (USA). The aim of this trial is to compare the efficacy and safety of insulin degludec/liraglutide (IDegLira) and insulin degludec (IDeg) in subjects with type 2 diabetes. Subjects continue their pre-trial treatment with metformin throughout the entire trial.

Treatments tested

insulin degludec/liraglutide Drug

IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
insulin degludec Drug

IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.

Main thing measured	Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01392573 ↗